Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Graft vs Host Disease 1

Interventions

fludarabine phosphate 5Cyclophosphamide 5Azacitidine 4Thiotepa 3Stem Cell Transplantation 3Melphalan 3Gemtuzumab 3Decitabine 3Cytarabine 3Busulfan 3venetoclax 2Radiotherapy 2Methylprednisolone 2Interferon alpha-2 2Injections 2Filgrastim 2Etoposide 2Emapalumab 2Cyclosporine 2Cladribine 2Antilymphocyte Serum 2vosaroxin 1vedolizumab 1trametinib 1tipifarnib 1thymoglobulin 1peginterferon alfa-2b 1peginterferon alfa-2a 1nilotinib 1midostaurin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Abatacept × Myeloid × Clear all
NCT06475820 2024-08-23

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Active not recruiting
150 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡